GALD Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 76.10 |
| 52 Week High | CHF 119.60 |
| 52 Week Low | CHF 62.39 |
| Beta | 0 |
| 1 Month Change | -15.59% |
| 3 Month Change | -30.06% |
| 1 Year Change | 19.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 18.91% |
Recent News & Updates
The Price Is Right For Galderma Group AG (VTX:GALD) Even After Diving 27%
Apr 05
Galderma Group AG Just Beat EPS By 26%: Here's What Analysts Think Will Happen Next
Mar 08Recent updates
The Price Is Right For Galderma Group AG (VTX:GALD) Even After Diving 27%
Apr 05Galderma Group AG Just Beat EPS By 26%: Here's What Analysts Think Will Happen Next
Mar 08Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?
Dec 18These 4 Measures Indicate That Galderma Group (VTX:GALD) Is Using Debt Reasonably Well
Oct 27Shareholder Returns
| GALD | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -2.8% | -1.1% | 1.2% |
| 1Y | 19.5% | 4.6% | -3.2% |
Return vs Industry: GALD exceeded the Swiss Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: GALD exceeded the Swiss Market which returned -3.2% over the past year.
Price Volatility
| GALD volatility | |
|---|---|
| GALD Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in CH Market | 8.5% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: GALD's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: GALD's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,545 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| GALD fundamental statistics | |
|---|---|
| Market cap | CHF 18.07b |
| Earnings (TTM) | CHF 188.43m |
| Revenue (TTM) | CHF 3.62b |
95.9x
P/E Ratio5.0x
P/S RatioIs GALD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALD income statement (TTM) | |
|---|---|
| Revenue | US$4.44b |
| Cost of Revenue | US$1.36b |
| Gross Profit | US$3.09b |
| Other Expenses | US$2.85b |
| Earnings | US$231.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 24, 2025
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 69.48% |
| Net Profit Margin | 5.20% |
| Debt/Equity Ratio | 33.9% |
How did GALD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 05:48 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galderma Group AG is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bethan Davies | Berenberg |
| Fulvio Cazzol | Berenberg |
| Richard Parkes | BNP Paribas Exane |